Skip to content

Find our latest news, stories and press releases

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

  1. Home/
  2. News/
  3. Health & wellness/
  4. Diabesity: The pandemic impacting populations around the globe
Diabesity: Global Epidemic Lede

Diabesity: The pandemic impacting populations around the globe

Obesity and diabetes rates are increasing so much that there’s a term for it: diabesity. Here’s what you should know about this worldwide health crisis.

They’re sobering statistics. Between 1980 and 2013, the number of overweight and obese people grew from 857 million to 2.1 billion globally. Today, over a quarter of those who are obese also have type 2 diabetes.
On their own, obesity and diabetes can lead to serious health complications —but when combined, “diabesity,” as experts are calling the simultaneous rise in both conditions, can really leave a detrimental mark on the health of people in nearly every corner of the globe.

As we mark World Diabetes Day on November 14, see how Johnson & Johnson is lending its support to help with the health crisis—and what steps you can take to be your best, healthy self.

Diabesity: A Global Pandemic Infographic-compressed.jpg

Here’s how you can learn more about the growing impact of diabetes and obesity around the world.

More from Johnson & Johnson

6 ways Johnson & Johnson is using AI to help advance healthcare

Artificial intelligence is revolutionizing healthcare—from improving surgical training and procedures to equipping healthcare providers with insights and personalizing care for patients around the world. See how the company is harnessing its extraordinary power.

How Johnson & Johnson is advancing the fight against Alzheimer’s disease

After decades of commitment to understanding this neurodegenerative disease, company scientists have developed innovative therapies and tools that can potentially slow its progression and ease the psychological toll on patients and caretakers. A cure is still elusive—but preventing the disease may be within reach.

Is this the end of one-size-fits-all treatments for depression?

Learn how Johnson & Johnson is working to better address the needs of the 7 in 10 people with depression whose treatments aren’t providing enough relief.